RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+50.37%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.65B
AUM Growth
+$3.65B
(+51%)
Cap. Flow
+$447M
Cap. Flow
% of AUM
12.25%
Top 10 Holdings %
Top 10 Hldgs %
23.51%
Holding
147
New
14
Increased
83
Reduced
11
Closed
4
Top Buys
| 1 |
Novavax
NVAX
|
$47.6M |
| 2 |
Centene
CNC
|
$35.9M |
| 3 |
UnitedHealth
UNH
|
$31M |
| 4 |
Edwards Lifesciences
EW
|
$26.8M |
| 5 |
Royalty Pharma
RPRX
|
$24.3M |
Top Sells
| 1 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
$42.7M |
| 2 |
Intuitive Surgical
ISRG
|
$18.5M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$7.9M |
| 4 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$7.48M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$5.41M |
Sector Composition
| 1 | Healthcare | 92.16% |
| 2 | Consumer Staples | 1.09% |
| 3 | Consumer Discretionary | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVTA
26
DELISTED
Invitae Corporation
NVTA
| $45.8M | 1.26% | 1,511,127 +361,127 | +31% | +$10.9M |
|
27
Mersana Therapeutics
MRSN
$36.5M
| $44M | 1.21% | 1,878,428 +645,428 | +52% | +$15.1M |
|
|
SGEN
28
DELISTED
Seagen Inc. Common Stock
SGEN
| $42.5M | 1.17% | 250,000 +8,000 | +3% | +$1.36M |
|
|
PTLA
29
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $41.5M | 1.14% | 2,306,196 +554,296 | +32% | +$9.97M |
|
30
Idexx Laboratories
IDXX
$51.8B
| $41.3M | 1.13% | 125,000 | – | – |
|
|
ONC
31
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $40.5M | 1.11% | 215,000 +200 | +0.1% | +$37.7K |
|
|
32
Edwards Lifesciences
EW
$47.8B
| $40.2M | 1.1% | 582,000 +388,000 | +200% | +$26.8M |
|
33
Freshpet
FRPT
$2.72B
| $39.8M | 1.09% | 476,000 +78,500 | +20% | +$6.57M |
|
|
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $39.8M | 1.09% | 348,761 +7,261 | +2% | +$829K |
|
35
Align Technology
ALGN
$10.3B
| $39.2M | 1.08% | 143,000 +15,500 | +12% | +$4.25M |
|
36
Boston Scientific
BSX
$156B
| $38.6M | 1.06% | 1,100,000 | – | – |
|
37
Penumbra
PEN
$10.6B
| $37M | 1.02% | 207,000 -18,000 | -8% | -$3.22M |
|
38
Exact Sciences
EXAS
$8.98B
| $36.9M | 1.01% | 424,000 | – | – |
|
39
Vertex Pharmaceuticals
VRTX
$100B
| $36.3M | 1% | 125,000 | – | – |
|
40
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $36.2M | 0.99% | 2,025,275 +75,275 | +4% | +$1.34M |
|
41
Applied Therapeutics
APLT
$71M
| $35.8M | 0.98% | 991,573 +145,873 | +17% | +$5.27M |
|
42
Assembly Biosciences
ASMB
$190M
| $35M | 0.96% | 1,498,915 -1,085 | -0.1% | -$25.3K |
|
43
Ardelyx
ARDX
$1.53B
| $34.7M | 0.95% | 5,015,109 +165,109 | +3% | +$1.14M |
|
44
Galapagos
GLPG
$2.07B
| $34.5M | 0.95% | 175,000 | – | – |
|
|
EPZM
45
DELISTED
Epizyme, Inc
EPZM
| $33.8M | 0.93% | 2,104,084 +149,084 | +8% | +$2.39M |
|
|
AMRN
46
Amarin Corp
AMRN
$311M
| $32.2M | 0.88% | 4,650,000 | – | – |
|
47
Ascendis Pharma
ASND
$11.8B
| $31.6M | 0.87% | 213,500 | – | – |
|
48
Cigna
CI
$80.3B
| $30.2M | 0.83% | 161,000 +20,000 | +14% | +$3.75M |
|
49
Amgen
AMGN
$155B
| $29.7M | 0.82% | 126,000 | – | – |
|
50
Madrigal Pharmaceuticals
MDGL
$9.76B
| $28.8M | 0.79% | 254,268 +4,268 | +2% | +$483K |
|